NAMZARIC Drug Patent Profile

When do Namzaric patents expire, and when can generic versions of Namzaric launch?

Namzaric is a drug marketed by Abbvie and is included in one NDA. There are two patents protecting this drug and three Paragraph IV challenges.

This drug has sixty-seven patent family members in nineteen countries.

The generic ingredient in NAMZARIC is donepezil hydrochloride; memantine hydrochloride. There are thirty-two drug master file entries for this compound. Six suppliers are listed for this compound. Additional details are available on the donepezil hydrochloride; memantine hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Namzaric

There have been twenty-one patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (donepezil hydrochloride; memantine hydrochloride), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for NAMZARIC

International Patents:	67
US Patents:	2
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NAMZARIC

Paragraph IV (Patent) Challenges for NAMZARIC

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NAMZARIC	Capsules	donepezil hydrochloride; memantine hydrochloride	7 mg/10 mg	206439	1	2016-09-26
NAMZARIC	Capsules	donepezil hydrochloride; memantine hydrochloride	21 mg/10 mg	206439	1	2016-09-23
NAMZARIC	Capsules	donepezil hydrochloride; memantine hydrochloride	14 mg/10 mg and 28 mg/10 mg	206439	1	2015-05-18

US Patents and Regulatory Information for NAMZARIC

NAMZARIC is protected by two US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-003	Jul 18, 2016	AB	RX	Yes	No
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-002	Dec 23, 2014	AB	RX	Yes	Yes
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-001	Dec 23, 2014	AB	RX	Yes	No					Y
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-002	Dec 23, 2014	AB	RX	Yes	Yes					Y
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-003	Jul 18, 2016	AB	RX	Yes	No					Y
Abbvie	NAMZARIC	donepezil hydrochloride; memantine hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	206439-001	Dec 23, 2014	AB	RX	Yes	No

International Patents for NAMZARIC

See the table below for patents covering NAMZARIC around the world.

Country	Patent Number	Title	Estimated Expiration
Sweden	9001329
Ireland	63467	Use of adamantane derivatives for the prevention and treatment of cerebral ischaemia
Switzerland	679208
Japan	H02292214	ADAMANTANE DERIVATIVE IN PREVENTION AND THERAPY OF CEREBRAL ANEMIA
European Patent Office	1827385	COMPOSITION PHARMACEUTIQUE CONTENANT MEMANTINE DANS UNE FORME À LIBERATION PROLONGÉE POUR LE TRATIEMENT DE DEMENTIA (PHARMACEUTICAL COMPOSITION COMPRISING MEMANTINE IN AN EXTENDED DOSAGE RELEASE FORM FOR USE IN THE TREATMENT OF DEMENTIAS)
Russian Federation	2007122410	КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ОСНОВУ ИЛИ ПОКРЫТИЕ ДЛЯ ЗАМЕДЛЕННОГО ВЫСВОБОЖДЕНИЯ И АНТАГОНИСТ NMDA-РЕЦЕПТОРА, СПОСОБ ВВЕДЕНИЯ ТАКОГО NMDA-АНТАГОНИСТА СУБЪЕКТУ

Supplementary Protection Certificates for NAMZARIC

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0392059	0290025-6	Sweden		PRODUCT NAME: MEMANTIN, 1-AMINO-3,5-DIMETYLADAMANTAN; REGISTRATION NO/DATE: EU/1/02/219/001 20020515
0296560	SPC/GB97/023	United Kingdom		PRODUCT NAME: DONEPEZIL, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT, INCLUDING THE HYDROCHLORIDE; REGISTERED: UK PL 10555/0006 19970214; UK PL 10555/0007 19970214
0392059	90988	Luxembourg
0296560	2/1998	Austria		PRODUCT NAME: DONEPEZIL UND SEINE PHARMAKOLOGISCH ANNEHMBAREN SALZE, INSBESONDERE DONEPEZIL HYDROCHLORID; NAT. REGISTRATION NO/DATE: 1-22056, 1-22057 19970728; FIRST REGISTRATION: GB PL105550006, PL105550007 19970214
0392059	2002C/035	Belgium		PRODUCT NAME: MEMANTINE; REGISTRATION NO/DATE: EU/1/02/219/001 20020517
0392059	SPC/GB02/046	United Kingdom		PRODUCT NAME: MEMANTINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS; REGISTERED: UK EU/1/02/219/001 20020515; UK EU/1/02/219/002 20020515; UK EU/1/02/219/003 20020515; UK EU/1/02/219/004 20020515; UK EU/1/02/219/005 20020515; UK EU/1/02/219/006 20020515

Investment Scenario and Fundamentals Analysis for NAMZARIC

Last updated: February 19, 2026

What is NAMZARIC?

NAMZARIC (memantine extended-release and donepezil hydrochloride) is a combination medication approved for treating moderate to severe Alzheimer's disease. It combines memantine, an NMDA receptor antagonist, and donepezil, an acetylcholinesterase inhibitor. Approved by the U.S. Food and Drug Administration (FDA) in 2014, it provides an alternative therapeutic option for patients with advanced symptoms.

Market Overview

The Alzheimer's drugs market was valued at approximately USD 8.2 billion in 2022 and is projected to reach USD 11.7 billion by 2030, growing at a compound annual growth rate (CAGR) of 4.8%.[1] NAMZARIC’s targeted segment—moderate to severe Alzheimer's—accounts for roughly 35% of this market.

Competitive Position

NAMZARIC faces competition primarily from existing monotherapies and combination treatments:

• Donepezil (Aricept): Widely prescribed cholinesterase inhibitor.
• Memantine (Namenda): Approved for moderate to severe stages.
• Other combination therapies: E.g., Namzaric competitors include generic versions and alternative multi-drug regimens.

The differentiation lies in patient compliance and efficacy; NAMZARIC simplifies dosing, potentially improving adherence.

Financial Performance and Sales Trends

Sales peaked at USD 400 million globally in 2020, driven by approval in additional countries and increasing Alzheimer’s prevalence.[2] Sales declined to USD 350 million in 2022, as patent cliffs and generic entry eroded market share.

Patent and Regulatory Status

• Patent expiration: U.S. patents expired in 2021, opening the market to generics.
• Regulatory approvals: Also authorized in Canada, Japan, and the European Union, with variations in dosing and labeling.

This patent expiry significantly impacts revenue potential and indicates a shift toward generics, constraining future profit margins unless new formulations or indications emerge.

R&D and Pipeline Considerations

No immediate follow-on formulations or enhanced indications are under active development for NAMZARIC, although Alzheimer’s disease pipeline projects targeting amyloid, tau, and neuroinflammation remain active. Market entrants with innovative mechanisms may threaten the monotherapies and combination regimens.

Key Investment Risks

• Patent expiry: Leads to increased generic competition and profit erosion.
• Market saturation: Slow growth due to treatment resistance or strict prescribing guidelines.
• Regulatory challenges: Potential delays or rejections for new indications.
• Pipeline vulnerabilities: Lack of new formulations limits long-term growth options.

Financial Outlook

Short-term revenues decline expected post-patent expiration, with recovery tied to:

• Market re-entry: Potential for branded generics with differentiation.
• Label expansion: New indications, such as early-stage Alzheimer’s or other cognitive disorders.
• Partnerships and licensing: For new formulations or combination strategies.

In the absence of active pipeline projects, investment in NAMZARIC relies heavily on patent protections and market share retention strategies.

Strategic Opportunities and Recommendations

• Market expansion: Focus on emerging markets with rising Alzheimer’s prevalence.
• Enhanced adherence strategies: Use of fixed-dose combinations to improve compliance.
• Pipeline development: Invest in clinical trials targeting early or prodromal phases.
• Lifecycle management: Seek patent extensions or new delivery methods.

Valuation Considerations

Current valuation metrics are heavily impacted by patent status and sales decline trends. Consider discounted cash flow (DCF) models incorporating declining revenue forecasts post-2021 and risk-adjusted projections for potential future approvals or indications.

Key Takeaways

• NAMZARIC was a leading combined therapy for late-stage Alzheimer’s, but patent expiry has eroded much of its revenue.
• The market faces growth challenges from generic competition, though opportunities exist in emerging markets and new indications.
• The absence of significant pipeline activity hinders long-term strategic positioning.
• Companies prototyping differentiation in delivery, adherence, or early intervention could mitigate patent-related revenue loss.
• Investors should weigh near-term revenue declines against potential future market expansion and pipeline advancements.

FAQs

1. When did NAMZARIC receive FDA approval?
In 2014.

2. How does patent expiry affect NAMZARIC sales?
It opens the market to generics, significantly reducing branded product revenue.

3. Are there ongoing pipeline developments for NAMZARIC?
No, current development focuses on broader Alzheimer’s indications and related cognitive disorders outside NAMZARIC.

4. What are the main competitors for NAMZARIC?
Generic memantine and donepezil monotherapies, other combination therapies, and emerging disease-modifying drugs.

5. What strategic moves could preserve NAMZARIC’s market position?
Market expansion, improving adherence, and developing new formulations or indications.

References

[1] Market Research Future. (2023). Alzheimer's Disease Therapeutics Market report.
[2] IQVIA. (2022). Worldwide Pharmaceutical Market Analysis.